NDA 208694 · Harrow Eye
Zerviate
Cetirizine Hydrochloride · Ophthalmic · Histamine-1 Receptor Antagonist
Priority reviewLast checked: Nov 20, 2026Latest source record: Feb 5, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
May 30, 2017
Approved uses
1
Original approval plus efficacy supplements
Registered trials
134
35 Phase 3, 7 recruiting
FAERS reports
43,309
34,381 serious, 5,083 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 3, 2026.
ZERVIATE ® (cetirizine ophthalmic solution) 0.24% is indicated for the treatment of ocular itching associated with allergic conjunctivitis. ZERVIATE ® (cetirizine ophthalmic solution) 0.24% is a histamine-1 (H1) receptor antagonist indicated for treatment of ocular itching associated with allergic conjunctivitis. ( 1 )
Mechanism: ZERVIATE ® , an antihistamine, is a histamine-1 (H1) receptor antagonist. Its effects are mediated via selective inhibition of H1 histamine receptors. The antihistaminic activity of cetirizine has been documented in a variety of animal and human models. In vivo and ex vivo animal models have shown negligible anticholinergic and antiserotonergic activity. In vitro receptor binding studies have shown no measurable affinity for other than H1 receptors.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 30, 2017 Original approval · Type 3 - New Dosage Form · priority review LabelLetterPediatric Written Request
1 products under this application
- ZERVIATE · CETIRIZINE HYDROCHLORIDE EQ 0.24% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cetirizine" as an intervention, any sponsor and status, largest first.
- Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00974571 · 1,365 participants · Start Nov 2001 · Primary completion May 2002
Drug: montelukast sodium; Comparator: cetirizine and 1 more · For: Perennial Allergic Rhinitis
- Combination Study Of S-555739/Cetirizine HCl In Adult Patients With Seasonal Allergic RhinitisPivotal-lookingCompleted
ShionogiIndustry
NCT01651871 · 779 participants · Start Jul 2012 · Primary completion Nov 2012
Drug: S-555739 Dose 1; S-555739 Dose 2 and 3 more · For: Seasonal Allergic Rhinitis
- Efficacy Study for the Symptomatic Treatment of Seasonal Allergic RhinitisPivotal-lookingCompleted
Faes Farma, S.A.Industry
NCT00504933 · 683 participants · Start May 2005 · Primary completion Nov 2005
Drug: bilastine; Cetirizine and 1 more · For: Seasonal Allergic Rhinitis
Johnson & Johnson Consumer and Personal Products WorldwideJohnson & Johnson (Janssen) (JNJ)
NCT02932774 · 683 participants · Start Mar 2001 · Primary completion Jul 2001
Drug: Cetirizine; Loratadine · For: Allergic Rhinitis; Hay Fever; SAR and 1 more
- A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic RhinitisPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01916226 · 682 participants · Start Aug 1, 2013 · Primary completion Oct 1, 2013
Drug: FPNS; FPNS Placebo and 2 more · For: Rhinitis, Allergic, Perennial and Seasonal
Sites: Little Rock, Arkansas; Denver, Colorado; Aventura, Florida · 31 sites in all
- Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety ExtensionPivotal-lookingCompleted
Faes Farma, S.A.Industry
NCT01127620 · 650 participants · Start May 2004 · Primary completion Mar 2006
Drug: Bilastine; Cetirizine and 1 more · For: Perennial Allergic Rhinitis
- Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic RhinitisPivotal-lookingCompleted
Idorsia Pharmaceuticals Ltd.Industry
NCT01484119 · 630 participants · Start Dec 2011 · Primary completion Feb 2012
Drug: ACT-129968; Placebo and 1 more · For: Seasonal Allergic Rhinitis
Sites: Austin, Texas; Kerrville, Texas; New Braunfels, Texas · 7 sites in all
- Study of ACT-129968 in Adult Patients With Seasonal Allergic RhinitisPivotal-lookingCompleted
Idorsia Pharmaceuticals Ltd.Industry
NCT01241214 · 579 participants · Start Nov 2010 · Primary completion Feb 2011
Drug: ACT-129968; ACT-129968 and 2 more · For: Seasonal Allergic Rhinitis
Sites: Austin, Texas; Kerrville, Texas; New Braunfels, Texas · 7 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue5,853
- drug ineffective5,324
- pain5,158
- rash5,124
- off label use4,634
- dyspnoea4,628
- pruritus4,543
- arthralgia4,078
- pyrexia3,959
- hypersensitivity3,788
- headache3,709
- nausea3,701
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 9 |
| 2006 | 34 |
| 2007 | 1 |
| 2008 | 14 |
| 2009 | 149 |
| 2010 | 51 |
| 2011 | 139 |
| 2012 | 575 |
| 2013 | 732 |
| 2014 | 1,189 |
| 2015 | 1,657 |
| 2016 | 2,030 |
| 2017 | 2,063 |
| 2018 | 2,874 |
| 2019 | 3,253 |
| 2020 | 3,691 |
| 2021 | 4,135 |
| 2022 | 3,599 |
| 2023 | 3,845 |
| 2024 | 4,820 |
| 2025 | 5,075 |
| 2026 | 3,370 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zerviate (Cetirizine HCl)
2024 spending
$3.9M
Beneficiaries
3,309
10,118 claims
Per beneficiary
$1,164
$7.31 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,644,591 |
| 2021 | $8,220,413 |
| 2022 | $4,350,525 |
| 2023 | $8,592,881 |
| 2024 | $3,852,825 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Acupuncture for allergic rhinitis: a systematic review and meta-analysis.
He M, Qin W, Qin Z, et al. · Eur J Med Res 2022 · Meta-Analysis, Systematic Review
- Efficacy and Safety of Oral Antihistamines for Allergic Rhinitis: Network Meta-Analysis.
Vieira RJ, Gil-Mata S, Ferreira A, et al. · J Allergy Clin Immunol Pract 2026 · Network Meta-Analysis, Systematic Review
- Antihistamines for atopic dermatitis (eczema): systematic review and network meta-analysis of randomised trials.
Chu AWL, Wen A, Guyatt GH, et al. · BMJ 2026 · Systematic Review, Network Meta-Analysis
- Interventions for pityriasis rosea.
Contreras-Ruiz J, Peternel S, Jiménez Gutiérrez C, et al. · Cochrane Database Syst Rev 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Comparative Safety Profiles of Individual Second-Generation H1-Antihistamines for the Treatment of Chronic Urticaria: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Chaichan W, Ruengorn C, Thavorn K, et al. · J Allergy Clin Immunol Pract 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Interventions for postburn pruritus.
Sinha S, Gabriel VA, Arora RK, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Meta-Analysis
Sponsor: Harrow Eye
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.